Also, by using a cell-based assay on A549 NSCLC cells, Choi and coworkers screened almost 4000 clinical compounds, leading to the identification of the glucocorticoid clobetasol propionate (CP), a drug used to treat dermatologic disorders, as a potent NRF2 inhibitor. Here, NFE2L2 is linked to non-small cell lung carcinoma.